NP-G2-044
Phase 1Small molecule
NP-G2-044 is one of 72 small molecule programs targeting Metastasis. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Imfinzi
AstraZenecaPhase 3
Votrient
NovartisPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Nolvadex
AstraZenecaPhase 3
Bavencio
EMD SeronoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Single Dose of
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastasis1 trial
Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NP-G2-044. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNovita Pharmaceuticals, Inc.